- Home
- PSFE vs TSHA Comparison
PSFE vs TSHA Comparison
Compare PSFE & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSFE
- TSHA
- Stock Information
- Founded
- PSFE 1996
- TSHA 2019
- Country
- PSFE United Kingdom
- TSHA United States
- Employees
- PSFE N/A
- TSHA N/A
- Industry
- PSFE Business Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- PSFE Consumer Discretionary
- TSHA Health Care
- Exchange
- PSFE Nasdaq
- TSHA Nasdaq
- Market Cap
- PSFE 770.1M
- TSHA 728.4M
- IPO Year
- PSFE N/A
- TSHA 2020
- Fundamental
- Price
- PSFE $14.24
- TSHA $3.18
- Analyst Decision
- PSFE Sell
- TSHA Strong Buy
- Analyst Count
- PSFE 4
- TSHA 7
- Target Price
- PSFE $17.38
- TSHA $8.71
- AVG Volume (30 Days)
- PSFE 263.3K
- TSHA 3.4M
- Earning Date
- PSFE 08-12-2025
- TSHA 08-12-2025
- Dividend Yield
- PSFE N/A
- TSHA N/A
- EPS Growth
- PSFE N/A
- TSHA N/A
- EPS
- PSFE N/A
- TSHA N/A
- Revenue
- PSFE $1,676,391,000.00
- TSHA $8,098,000.00
- Revenue This Year
- PSFE $3.18
- TSHA N/A
- Revenue Next Year
- PSFE $7.05
- TSHA N/A
- P/E Ratio
- PSFE N/A
- TSHA N/A
- Revenue Growth
- PSFE 0.47
- TSHA N/A
- 52 Week Low
- PSFE $10.63
- TSHA $1.05
- 52 Week High
- PSFE $26.25
- TSHA $3.40
- Technical
- Relative Strength Index (RSI)
- PSFE 55.79
- TSHA 59.80
- Support Level
- PSFE $13.86
- TSHA $3.16
- Resistance Level
- PSFE $14.62
- TSHA $2.99
- Average True Range (ATR)
- PSFE 0.46
- TSHA 0.16
- MACD
- PSFE 0.02
- TSHA 0.02
- Stochastic Oscillator
- PSFE 59.16
- TSHA 66.67
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.